The event will highlight new preclinical data for VG-3927, discuss
current treatment approaches for AD, and Vigils TREM2-focused clinical approach for treating AD guided by its precision medicine strategy. Vigils management team will be joined by:
|
|
|
Marco Colonna, M.D., Robert Rock Belliveau Professor of Pathology & Immunology, Washington University
School of Medicine. Vigil Neuroscience Scientific Advisory Board Chairman; and, |
|
|
|
Samuel E. Gandy, Ph.D., M.D., Mount Sinai Professor of Alzheimers Disease Research, Professor of
Neurology & Psychiatry and Associate Director of Mount Sinai Alzheimers Disease Research Center. Past Chairman, National Medical & Scientific Advisory Council of the Alzheimers Association. |
To access the live webcast of this event, please register here or visit Events & Presentations in the Investors
section of the Vigil website at www.vigilneuro.com. An archived replay will be available for approximately 90 days following the presentation.
About VG-3927
Vigils highly active, selective, and brain-penetrant small molecule TREM2 agonist, VG-3927, is designed to act as
a molecular glue that potentiates the TREM2 signaling response to natural damage ligands. In preclinical studies, Vigil has established that VG-3927 demonstrated
on-target TREM2 activation across both common and rare TREM2 variants. Additionally, VG-3927 demonstrated preclinically that it was able to deliver in vivo TREM2
responses within the central nervous system at a magnitude and specificity similar to VGL101.
About Vigil Neuroscience
Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring
the vigilance of microglia, the sentinel immune cells of the brain. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of
patients and their families. VGL101, our lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal
spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. We are also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with
microglial dysfunction, with an initial focus on Alzheimers disease (AD) in genetically defined subpopulations.
Forward-Looking Statements
This press release includes certain disclosures that contain forward-looking statements of Vigil Neuroscience, Inc.s
(Vigil or the Company) that are made pursuant to the safe harbor provisions of the federal securities laws, including, without limitation, express or implied statements regarding: the timing for the commencement and dosing of
patients in VG-3927s Phase I trial; anticipated impact of the partial clinical hold on the Companys clinical development plans; regulatory progress, clinical progress and clinical development plans
for VG-3927; and expectations regarding the timing of additional regulatory information from the U.S. Food and Drug Administration (FDA). Factors that could cause actual results to differ include,
but are not limited to, risks and uncertainties related to uncertainties inherent in the development of product candidates, including risks and uncertainties related to the initiation and completion of clinical trials; Companys ability to
commence and recruit study subjects for clinical trials; the availability and timing of results and data from clinical trials; the timing and content of